Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 16Urethral Neoplasms 4Prostatic Neoplasms 4Testicular Neoplasms 3Testicular Germ Cell Tumor 2Teratoma 2Kidney Neoplasms 2Carcinoma, Renal Cell 2Urothelial Carcinoma of the Bladder 1Ureteral Neoplasms 1Seminoma 1Renal Pelvis and Ureter Urothelial Carcinoma 1Ovarian Neoplasms 1Ovarian Germ Cell Cancer 1Neoplasm Metastasis 1Muscle Invasive Bladder Urothelial Carcinoma 1Endodermal Sinus Tumor 1Carcinoma, Transitional Cell 1Carcinoma, Embryonal 1Bladder Adenocarcinoma 1

Interventions

pembrolizumab 92Gemcitabine 56Nivolumab 50Cisplatin 39atezolizumab 37Carboplatin 30avelumab 29enfortumab vedotin 26Docetaxel 23Magnetic Resonance Spectroscopy 19Mitomycin 17Ipilimumab 17Paclitaxel 16Specimen Handling 14durvalumab 11toripalimab 10sacituzumab govitecan 10Pemetrexed 10cabozantinib 9Taxes 8vinflunine 7Cyclophosphamide 7tislelizumab 6Injections 6Bevacizumab 6pemigatinib 5fludarabine 5disitamab vedotin 5Standard of Care 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × Vinblastine × Genitourinary × Clear all
NCT05137262 2026-02-18

A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
12 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡